196 related articles for article (PubMed ID: 22940424)
1. Reinforcing properties of Pramipexole in normal and parkinsonian rats.
Engeln M; Ahmed SH; Vouillac C; Tison F; Bezard E; Fernagut PO
Neurobiol Dis; 2013 Jan; 49():79-86. PubMed ID: 22940424
[TBL] [Abstract][Full Text] [Related]
2. Chronic pramipexole treatment induces compulsive behavior in rats with 6-OHDA lesions of the substantia nigra and ventral tegmental area.
Dardou D; Reyrolle L; Chassain C; Durif F
Behav Brain Res; 2017 Aug; 332():327-336. PubMed ID: 28634107
[TBL] [Abstract][Full Text] [Related]
3. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
[TBL] [Abstract][Full Text] [Related]
4. Dopamine receptor activation promotes adult neurogenesis in an acute Parkinson model.
Winner B; Desplats P; Hagl C; Klucken J; Aigner R; Ploetz S; Laemke J; Karl A; Aigner L; Masliah E; Buerger E; Winkler J
Exp Neurol; 2009 Oct; 219(2):543-52. PubMed ID: 19619535
[TBL] [Abstract][Full Text] [Related]
5. Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
Marin C; Bonastre M; Mengod G; Cortés R; Giralt A; Obeso JA; Schapira AH
Neurobiol Dis; 2014 Apr; 64():36-47. PubMed ID: 24370700
[TBL] [Abstract][Full Text] [Related]
6. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Fragment C Domain of Tetanus Toxin and Pramipexole in an Animal Model of Parkinson's Disease.
Patricio F; Parra I; Martínez I; Pérez-Severiano F; Montes S; Aguilera J; Limón ID; Tizabi Y; Mendieta L
Neurotox Res; 2019 Apr; 35(3):699-710. PubMed ID: 30607904
[TBL] [Abstract][Full Text] [Related]
8. Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats.
Jiménez-Urbieta H; Gago B; Quiroga-Varela A; Rodríguez-Chinchilla T; Merino-Galán L; Delgado-Alvarado M; Navalpotro-Gómez I; Belloso-Iguerategui A; Marin C; Rodríguez-Oroz MC
Psychopharmacology (Berl); 2020 Aug; 237(8):2419-2431. PubMed ID: 32440779
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologically distinct pramipexole-mediated akinesia vs. risk-taking in a rat model of Parkinson's disease.
Holtz NA; Tedford SE; Persons AL; Grasso SA; Napier TC
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Oct; 70():77-84. PubMed ID: 27216282
[TBL] [Abstract][Full Text] [Related]
10. Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls.
Riddle JL; Rokosik SL; Napier TC
Behav Brain Res; 2012 Jul; 233(1):15-23. PubMed ID: 22727039
[TBL] [Abstract][Full Text] [Related]
11. Dopamine agonists increase perseverative instrumental responses but do not restore habit formation in a rat model of Parkinsonism.
Faure A; Leblanc-Veyrac P; El Massioui N
Neuroscience; 2010 Jun; 168(2):477-86. PubMed ID: 20362642
[TBL] [Abstract][Full Text] [Related]
12. An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease.
Jones CA; Johnston LC; Jackson MJ; Smith LA; van Scharrenburg G; Rose S; Jenner PG; McCreary AC
Eur Neuropsychopharmacol; 2010 Aug; 20(8):582-93. PubMed ID: 20434890
[TBL] [Abstract][Full Text] [Related]
13. Anterior ventral tegmental area dopaminergic neurons are not involved in the motivational effects of bromocriptine, pramipexole and cocaine in drug-free rats.
Ouachikh O; Dieb W; Durif F; Hafidi A
Behav Brain Res; 2014 Apr; 262():1-7. PubMed ID: 24361908
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
15. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons.
Du F; Li R; Huang Y; Li X; Le W
Eur J Neurosci; 2005 Nov; 22(10):2422-30. PubMed ID: 16307585
[TBL] [Abstract][Full Text] [Related]
16. Substantia nigra glutamate antagonists produce contralateral turning and basal ganglia Fos expression: interactions with D1 and D2 dopamine receptor agonists.
McPherson RJ; Marshall JF
Synapse; 2000 Jun; 36(3):194-204. PubMed ID: 10819899
[TBL] [Abstract][Full Text] [Related]
17. Effect of long-term treatment with pramipexole or levodopa on presynaptic markers assessed by longitudinal [123I]FP-CIT SPECT and histochemistry.
Depboylu C; Maurer L; Matusch A; Hermanns G; Windolph A; Béhé M; Oertel WH; Höglinger GU
Neuroimage; 2013 Oct; 79():191-200. PubMed ID: 23631981
[TBL] [Abstract][Full Text] [Related]
18. Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson's disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats.
Ferger B; Buck K; Shimasaki M; Koros E; Voehringer P; Buerger E
Synapse; 2010 Jul; 64(7):533-41. PubMed ID: 20196139
[TBL] [Abstract][Full Text] [Related]
19. D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism.
Ballion B; Frenois F; Zold CL; Chetrit J; Murer MG; Gonon F
Neurobiol Dis; 2009 Sep; 35(3):376-84. PubMed ID: 19501163
[TBL] [Abstract][Full Text] [Related]
20. In vivo dopamine agonist properties of rotigotine: Role of D1 and D2 receptors.
Fenu S; Espa E; Pisanu A; Di Chiara G
Eur J Pharmacol; 2016 Oct; 788():183-191. PubMed ID: 27343381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
